SkyePharma drops on drug delay

Drug delivery company SkyePharma said yesterday it will need to do more tests on its asthma drug Flutiform, pushing the expected US approval out to late 2011 and sending its shares down 8.6 per cent to 103.68p. The company has been told by the US Food and Drug Administration that further tests will be required to get more data on the effects of different doses.